Abstract:Patients with myocardial ischemia and infarction are at increased risk of arrhythmias, which in turn, can exacerbate the overall risk of mortality. Despite the observed reduction in recurrent arrhythmias through antiarrhythmic drug therapy, the precise mechanisms underlying their effectiveness in treating ischemic heart disease remain unclear. Moreover, there is a lack of specialized drugs designed explicitly for the treatment of myocardial ischemic arrhythmia. This study employs an electrophysiological simulation approach to investigate the potential antiarrhythmic effects and underlying mechanisms of various pharmacological agents in the context of ischemia and myocardial infarction (MI). Based on physiological experimental data, computational models are developed to simulate the effects of a series of pharmacological agents (amiodarone, telmisartan, E-4031, chromanol 293B, and glibenclamide) on cellular electrophysiology and utilized to further evaluate their antiarrhythmic effectiveness during ischemia. On 2D and 3D tissues with multiple pathological conditions, the simulation results indicate that the antiarrhythmic effect of glibenclamide is primarily attributed to the suppression of efflux of potassium ion to facilitate the restitution of [K + ] o , as opposed to recovery of I KATP during myocardial ischemia. This discovery implies that, during acute cardiac ischemia, pro-arrhythmogenic alterations in cardiac tissue's excitability and conduction properties are more significantly influenced by electrophysiological changes in the depolarization rate, as opposed to variations in the action potential duration (APD). These findings offer specific insights into potentially effective targets for investigating ischemic arrhythmias, providing significant guidance for clinical interventions in acute coronary syndrome. In acute coronary syndrome, the progression of ischemic, injury, and infarction conditions heightens the risk of ischemic cardiac arrhythmias. Despite the existence of various antiarrhythmic drugs, there remains a scarcity of medications specifically tailored for ischemic cardiac arrhythmias. Moreover, comprehending the diverse drug responses in tissues with multiple ischemic conditions (ischemia 1a, 1b, and infarction) remains incomplete. Therefore, in this study, mathematical models depicting the electrophysiological remodeling induced by different drugs such as amiodarone, telmisartan, E-4031, chromanol 293B, and glibenclamide, are constructed and integrated into multi-scale computational models to assess their antiarrhythmic effects. Simulation results demonstrate the potential of glibenclamide in mitigating ischemic cardiac arrhythmias. It can be attributed to its ability not only to improve the depolarization phase's membrane potential by inhibiting extracellular potassium accumulation during the ischemic stage, leading to an increased dV/dt max , but also to extend the action potential duration (APD) by suppressing I KATP . Finally, the application of glibenclamide results in heightened conduction velocity and prolonged APD at the tissue level. Consequently, these effects enlarge the wavelength of excitation waves, ultimately reducing the vulnerable window for reentrant wave and exhibiting an anti-ischemic arrhythmic effect. More importantly, it's shown that glibenclamide's inhibition of [K + ] o yields a more significant impact on antiarrhythmic effects compared to its prolongation of APD. This is partly due to the more pronounced enhancement in the wavelength of excitation waves resulting from CV elevation compared with APD prolongation. Additionally, in tissues with coexisting multiple ischemic conditions, suppressing [K + ] o reduces the spatial dispersion of CV, especially at the boundaries of different ischemic tissues like ischemia 1b and infarction, facilitating a more uniform excitation wave propagation. This study offers insights into the anti-arrhythmic mechanisms of established agents during acute coronary syndrome and identifies potential targets for novel anti-arrhythmic drug development.

Design, Synthesis and Biological Evaluation of 4-Chromanone Derivatives As I-Kr Inhibitors

Molecular Hybridization, Synthesis, and Biological Evaluation of Novel Chroman IKr and IKs Dual Blockers

Design, Synthesis and Biological Activities of Benzo[d]imidazo[1,2-A]imidazole Derivatives As TRPM2-specfic Inhibitors

Discovery of Aroyl Piperazine Derivatives As IKr & IKs Dual Inhibitors for Cardiac Arrhythmia Treatment.

Design and Bio-Evaluation of Indole Derivatives As Potent Kv1.5 Inhibitors

Challenges Faced with Small Molecular Modulators of Potassium Current Channel Isoform Kv1.5

Design, Synthesis and Biological Evaluation of Benzopyran Derivatives As KATP Channel Openers

Synthesis and In Vivo Antiarrhythmic Activity Evaluation of Novel Scutellarein Analogues as Voltage-Gated Nav1.5 and Cav1.2 Channels Blockers

Design, Synthesis, and Antiarrhythmic Activity of New Indole-3-carboxamide Derivatives

Rational Design and Synthesis of 3-Morpholine Linked Aromatic-Imino-1H-Indoles as Novel Kv1.5 Channel Inhibitors Sharing Vasodilation Effects

Discovery of 1-Aryloxyethyl Piperazine Derivatives As Kv1.5 Potassium Channel Inhibitors (part I).

Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing.

Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Pyrimidine Derivatives as Potential Calcium Channel Blockers

Design, Synthesis, and Negative Inotropic Evaluation of 4‐phenyl‐1h‐1,2,4‐triazol‐5(4h)‐one Derivatives Containing Triazole or Piperazine Moieties

Modulating the voltage sensor of a cardiac potassium channel shows antiarrhythmic effects

Structural investigation of Keap1-Nrf2 protein-protein interaction (PPI) Inhibitors for treating myocarditis through molecular simulations

The Research Practice of Anti-Arrhythmic Agents Targeting on Potassium Ion Channel

A simulation study on the antiarrhythmic mechanisms of established agents in myocardial ischemia and infarction

Strategies for Atrial Fibrillation Therapy: Focusing Onikurpotassium Channel

Inhibition of Late Sodium Current: A Novel Target to Treat Cardiac Arrhythmias

Rational Design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol Derivatives As Novel Bromodomain-Containing Protein 4 Inhibitors.